Protein degradation reaches further out

Discover the world’s best science and medicine | Nature.com

Email Bluesky Facebook LinkedIn Reddit Whatsapp X Access through your institution Buy or subscribe Although the development of efficient and selective small-molecule inhibitors and monoclonal antibodies has improved over the years, ‘undruggable’ proteins can still elude these established drug modalities. Targeted protein degradation with proteolysis-targeting chimaeras (PROTACs) has emerged as an attractive route to target these difficult proteins. However, this approach is limited to proteins that have intracellular domains, meaning that ~40% of the proteome is out of scope. Now, Bertozzi and

saved by

• Yu Ren Wang

related reading

• Lysosome-targeting chimaeras for degradation of extracellular proteins | Naturenature.com
• Lysosome-targeting chimeras evolve | Nature Chemical Biologynature.com
• Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
• The current state and future directions of RNAi-based therapeutics | Nature Reviews Drug Discoverynature.com
• Development of a targeted BioPROTAC degrader selective for misfolded SOD1nature.com
• Technologies to measure and modulate protein subcellular localizationnature.com
• PDB101: Molecule of the Month: PROTACs and Molecular Glue Degraderspdb101.rcsb.org
• Interspecies Differences in Proteome Turnover Kinetics Are Correlated With Life Spans and Energetic Demandsncbi.nlm.nih.gov
• Measure Proteins in Place - New Sciencenewscience.org
• The dTAG system for immediate and target-specific protein degradationpmc.ncbi.nlm.nih.gov
• Programmed exosome fusion for energy generation in living cellsnature.com
• Protein purification workflow – The Bumbling Biochemistthebumblingbiochemist.com